Article in Science immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Nicole M CarterDepartment of Biological Chemistry and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-4453-9027
Wihib D HankoreDepartment of Biological Chemistry and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0009-0007-3412-3921
Yong-Kang YangDepartment of Biological Chemistry and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-0333-7712
Chao YangDepartment of Biological Chemistry and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shelby M HutchersonDepartment of Biological Chemistry and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-8380-5012
Wyatt FalesDepartment of Biological Chemistry and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0009-0006-5885-7148
Anushka GhoshDepartment of Biological Chemistry and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-6699-7737
Piyusha MongiaDepartment of Biological Chemistry and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-3438-8974
Sophie MackinnonDepartment of Biological Chemistry and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Anna BrennanDepartment of Biological Chemistry and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Robert D LeoneBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-2983-8531
Joel L PomerantzDepartment of Biological Chemistry and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-5030-1018
Funding
BIOCHEMISTRY, CELLULAR AND MOLECULAR BIOLOGY PROGRAMT32GM007445 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI GREEN, RACHEL · 1985 to 2021
$24.1M
Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling IntegratorR01AI148143 · NIAID · JOHNS HOPKINS UNIVERSITY · PI POMERANTZ, JOEL L · 2020 to 2024
$2.3M
ENCAPSULATION OF PLASMODIUM PARASITES BY ANOPHELES GAMBIR01AI043053 · NIAID · YALE UNIVERSITY · PI ZHENG, LIANGBIAO · 1999 to 2003
$1.3M
Characterization of a novel suppressor of oncogenic CARD11 signaling.F31CA254167 · NCI · JOHNS HOPKINS UNIVERSITY · PI CARTER, NICOLE MARIE · 2020 to 2023
Antigen receptor signaling pathways that control lymphocyte activation depend on signaling hubs and negative regulatory proteins to fine-tune signaling outputs to ensure host defense and avoid pathogenic responses. Caspase recruitment domain-containing protein 11 (CARD11) is a critical signaling scaffold that translates T cell receptor (TCR) triggering into the activation of nuclear factor κB (NF-κB), c-Jun N-terminal kinase (JNK), mechanistic target of rapamycin (mTOR), and Akt. Here, we identify glutamine-rich protein 1 (QRICH1) as a regulator of CARD11 signaling that mediates an intracellular checkpoint for CD8
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
QRICH1 mediates an intracellular checkpoint for CD8 · full record | Socratic